SG Americas Securities LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

SG Americas Securities LLC boosted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONSFree Report) by 222.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,927 shares of the company’s stock after purchasing an additional 16,508 shares during the quarter. SG Americas Securities LLC’s holdings in Ionis Pharmaceuticals were worth $836,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after acquiring an additional 303 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth $40,000. Prospera Private Wealth LLC purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth $42,000. Itau Unibanco Holding S.A. boosted its position in shares of Ionis Pharmaceuticals by 40.9% during the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after acquiring an additional 314 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Ionis Pharmaceuticals during the third quarter worth $51,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Trading Down 3.6 %

Shares of IONS stock opened at $32.88 on Thursday. The company’s 50-day moving average price is $35.19 and its 200-day moving average price is $40.39. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. The stock has a market cap of $5.19 billion, a price-to-earnings ratio of -13.48 and a beta of 0.35. Ionis Pharmaceuticals, Inc. has a twelve month low of $31.40 and a twelve month high of $52.49.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, EVP Eric Swayze sold 1,194 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now directly owns 33,713 shares of the company’s stock, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 6,630 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 57,293 shares of company stock valued at $1,914,820 over the last 90 days. 2.71% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IONS. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, January 15th. Piper Sandler decreased their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Get Our Latest Report on IONS

About Ionis Pharmaceuticals

(Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Read More

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONSFree Report).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.